Idea or Concept – Page 2

Zymeworks Pivots to Royalty-Driven Model After Strong Ziihera Data in Gastric Cancer

4 weeks ago talkbio0Tagged Biological Factors, buyback, erbB-2 Receptor, Jazz, Malignant neoplasm of stomach, milestone payments, Regulatory Filing, Royalty-Driven Model, Strategy, Ziihera, Zymeworks

Zymeworks; royalty-driven model; Ziihera; gastric cancer; HER2; biologics; milestone payments; stock buyback; biotech strategy; Jazz Pharmaceuticals; regulatory filing

Spotlight On Obesity Week: Non-incretin Alternatives Turn Up the Heat

1 month ago talkbio0Tagged Adherence (attribute), Behavior, cardiometabolic, Contrave, craving control, Health, naltrexone-bupropion, non-incretin therapies, pharmaceutical innovation, Weight maintenance regimen

ObesityWeek 2025; non-incretin therapies; naltrexone-bupropion; CONTRAVE; weight management; craving control; behavioral adherence; pharmaceutical innovation; cardiometabolic health

Metsera Bidding War Grips Obesity Drug Field as Novo Nordisk and Pfizer Escalate Offers

1 month ago talkbio0Tagged Acquisition, Antitrust, bidding war, Disputes, Dominance, Glucagon-Like Peptide 1, Legal, Market, Metsera, Novo Nordisk, Obesity, Pfizer

Metsera; obesity drugs; bidding war; Novo Nordisk; Pfizer; acquisition; GLP-1; antitrust; market dominance; legal disputes

M42 and Oracle Join Forces to Advance Healthy Longevity and Disease Prevention

1 month ago talkbio0Tagged disease prevention, electronic health record - ActClassContainer, Emirati Genome Program, healthy longevity, Oracle Health, personalized healthcare, Pharmacogenomics, Precision Medicine, UAE

M42; Oracle Health; healthy longevity; disease prevention; precision medicine; Emirati Genome Program; pharmacogenomics; electronic health record (EHR); personalized healthcare; UAE

Expert Flags Potential ‘Honeymoon Effect’ as Rapport Heads Towards Phase III Epilepsy Trials

1 month ago talkbio0Tagged Biological Markers, drug-resistant focal seizures, Epilepsy, Honeymoon Effect, KOL Bulletin, mid-stage, Phase 3 Clinical Trials, RAP-219, Rapport Therapeutics, Seizures

KOL Bulletin; honeymoon effect; Rapport Therapeutics; RAP-219; Phase III trials; epilepsy; drug-resistant focal seizures; seizure reduction; mid-stage data; biomarker

Wave Life Sciences Obesity Biomarker Data Raise Hopes for Future Readouts

1 month ago talkbio0Tagged Activin E :* *, Biological Markers, Body Composition, Clinical Trials, INHBE gene, INLIGHT trial, Obesity, RNA therapeutics, RNA, Small Interfering, Wave Life Sciences, Weight Loss, WVE-007

Wave Life Sciences; WVE-007; obesity; biomarker data; siRNA; Activin E; INHBE gene; RNA therapeutics; clinical trial; body composition; weight loss; INLIGHT trial

Thomson Reuters Approved for $27.5 Million Data Privacy Settlement for Selling Californians’ Personal Data

2 months ago talkbio0Tagged California residents, class action, data privacy, personal data, Remote control command - Clear, settlement, Thomson Reuters

Thomson Reuters; CLEAR platform; data privacy; California residents; settlement; personal data; class action

RAPT Therapeutics Announces Proposed Public Offering of Common Stock

2 months ago talkbio0Tagged Biological Factors, conditions, Dilution technique, Gross (qualifier value), Immunology, Market, Pricing, public entity, RAPT

RAPT Therapeutics; public offering; common stock; underwritten offering; biopharmaceutical; immunology; market conditions; share dilution; offering pricing; gross proceeds

Accuray Accelerates Transformation Efforts with Appointments of Experienced Executive Leaders

2 months ago talkbio0Tagged Accuray, cell transformation, CEO, Change, Organizational, executive appointments, Leadership, med-tech, operational transformation, Steve La Neve, Suzanne Winter, Transition Mutation

Accuray; transformation; executive appointments; Steve La Neve; CEO; Suzanne Winter; organizational change; operational transformation; med-tech; leadership transition

Weight-loss drug stocks drop after Trump pledges major price cuts

2 months ago talkbio0Tagged Administration occupational activities, Drops - Drug Form, drug price, eli lilly, Glucagon-Like Peptide 1, Nordisk, Ozempic, Wegovy, Weight-Loss Agents

weight-loss drugs; ozempic; wegovy; novo nordisk; eli lilly; stock drop; drug pricing; trump administration; GLP-1